ATARA BIOTHERAPEUTICS, INC. Research and Development Expense
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Research and Development Expense of $1.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $1.34M, a 81.60% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $164.00K, a 99.40% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was -$223.00K, a 100.78% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $2.92M, a 93.34% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. research and development expense for fiscal 2025 was $37.45M, a 75.28% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. research and development expense for fiscal 2024 was $151.48M, a 32.61% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. research and development expense for fiscal 2023 was $224.78M, a 17.52% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. research and development expense for fiscal 2022 was $272.53M, a 3.36% decline from fiscal 2021.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.34M 10-Q · filed 2026-08-12 | $1.51M 10-Q · filed 2026-08-12 | $1.29M derived: sum of 3 quarters · filed 2026-08-12 | $4.21M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $164.00K 10-Q · filed 2026-05-12 | -$59.00K derived: sum of 2 quarters · filed 2026-05-12 | $2.87M derived: sum of 3 quarters · filed 2026-05-12 | $10.18M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | -$223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $2.70M derived: sum of 2 quarters · filed 2026-03-16 | $10.01M derived: sum of 3 quarters · filed 2026-08-12 | $37.45M 10-K · filed 2026-03-16 | ||
| 2025-09-30 | $2.92M 10-Q · filed 2025-11-12 | $10.23M derived: sum of 2 quarters · filed 2026-08-12 | $37.67M 10-Q · filed 2025-11-12 | $66.39M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $7.31M 10-Q · filed 2026-08-12 | $34.74M 10-Q · filed 2026-08-12 | $63.46M derived: sum of 3 quarters · filed 2026-08-12 | $107.39M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $27.43M 10-Q · filed 2026-05-12 | $56.15M derived: sum of 2 quarters · filed 2026-05-12 | $100.08M derived: sum of 3 quarters · filed 2026-05-12 | $133.41M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $28.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $72.64M derived: sum of 2 quarters · filed 2026-03-16 | $105.98M derived: sum of 3 quarters · filed 2026-03-16 | $151.48M 10-K · filed 2026-03-16 | ||
| 2024-09-30 | $43.92M 10-Q · filed 2025-11-12 | $77.26M derived: sum of 2 quarters · filed 2025-11-12 | $122.76M 10-Q · filed 2025-11-12 | $172.36M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $33.33M 10-Q · filed 2025-08-11 | $78.84M 10-Q · filed 2025-08-11 | $128.44M derived: sum of 3 quarters · filed 2025-08-11 | $185.33M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $45.51M 10-Q · filed 2025-05-15 | $95.11M derived: sum of 2 quarters · filed 2025-05-15 | $151.99M derived: sum of 3 quarters · filed 2025-05-15 | $208.13M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $49.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $106.49M derived: sum of 2 quarters · filed 2025-03-07 | $162.63M derived: sum of 3 quarters · filed 2025-03-07 | $224.78M 10-K · filed 2025-03-07 | ||
| 2023-09-30 | $56.89M 10-Q · filed 2024-11-12 | $113.03M derived: sum of 2 quarters · filed 2024-11-12 | $175.19M 10-Q · filed 2024-11-12 | $237.70M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $56.14M 10-Q · filed 2024-08-12 | $118.30M 10-Q · filed 2024-08-12 | $180.81M derived: sum of 3 quarters · filed 2024-08-12 | $250.97M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $62.16M 10-Q · filed 2024-05-09 | $124.67M derived: sum of 2 quarters · filed 2024-05-09 | $194.83M derived: sum of 3 quarters · filed 2024-05-09 | $259.73M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $62.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $132.67M derived: sum of 2 quarters · filed 2024-03-28 | $197.57M derived: sum of 3 quarters · filed 2024-03-28 | $272.53M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $70.16M 10-Q · filed 2023-11-01 | $135.06M derived: sum of 2 quarters · filed 2023-11-01 | $210.02M 10-Q · filed 2023-11-01 | $289.15M derived: sum of 4 quarters · filed 2023-11-01 | ||
| 2022-06-30 | $64.90M 10-Q · filed 2023-08-08 | $139.86M 10-Q · filed 2023-08-08 | $219.00M derived: sum of 3 quarters · filed 2023-08-08 | $289.33M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $74.96M 10-Q · filed 2023-05-08 | $154.10M derived: sum of 2 quarters · filed 2023-05-08 | $224.43M derived: sum of 3 quarters · filed 2023-05-08 | $292.90M derived: sum of 4 quarters · filed 2023-05-08 | ||
| 2021-12-31 | $79.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $149.47M derived: sum of 2 quarters · filed 2023-02-08 | $217.94M derived: sum of 3 quarters · filed 2023-02-08 | $282.00M 10-K · filed 2023-02-08 | ||
| 2021-09-30 | $70.33M 10-Q · filed 2022-11-08 | $138.81M derived: sum of 2 quarters · filed 2022-11-08 | $202.87M 10-Q · filed 2022-11-08 | $268.42M derived: sum of 4 quarters · filed 2023-02-08 | ||
| 2021-06-30 | $68.47M 10-Q · filed 2022-08-08 | $132.53M 10-Q · filed 2022-08-08 | $198.09M derived: sum of 3 quarters · filed 2023-02-08 | $257.96M derived: sum of 4 quarters · filed 2023-02-08 | ||
| 2021-03-31 | $64.06M 10-Q · filed 2022-05-05 | $129.61M derived: sum of 2 quarters · filed 2023-02-08 | $189.49M derived: sum of 3 quarters · filed 2023-02-08 | $251.05M derived: sum of 4 quarters · filed 2023-02-08 | ||
| 2020-12-31 | $65.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $125.43M derived: sum of 2 quarters · filed 2023-02-08 | $186.99M derived: sum of 3 quarters · filed 2023-02-08 | $244.65M 10-K · filed 2023-02-08 | ||
| 2020-09-30 | $59.88M 10-Q · filed 2021-11-04 | $121.44M derived: sum of 2 quarters · filed 2021-11-04 | $179.10M 10-Q · filed 2021-11-04 | $240.74M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $61.56M 10-Q · filed 2021-08-09 | $119.22M 10-Q · filed 2021-08-09 | $180.86M derived: sum of 3 quarters · filed 2022-02-28 | $234.40M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $57.66M 10-Q · filed 2021-05-04 | $119.30M derived: sum of 2 quarters · filed 2022-02-28 | $172.84M derived: sum of 3 quarters · filed 2022-02-28 | $225.09M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $61.64M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $115.18M derived: sum of 2 quarters · filed 2022-02-28 | $167.43M derived: sum of 3 quarters · filed 2022-02-28 | $216.10M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $53.54M 10-Q · filed 2020-11-09 | $105.79M derived: sum of 2 quarters · filed 2020-11-09 | $154.46M 10-Q · filed 2020-11-09 | $216.71M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-06-30 | $52.25M 10-Q · filed 2020-08-05 | $100.92M 10-Q · filed 2020-08-05 | $163.17M derived: sum of 3 quarters · filed 2021-03-01 | $206.53M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2019-03-31 | $48.67M 10-Q · filed 2020-05-06 | $110.92M derived: sum of 2 quarters · filed 2021-03-01 | $154.28M derived: sum of 3 quarters · filed 2021-03-01 | $187.66M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $62.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $105.61M derived: sum of 2 quarters · filed 2021-03-01 | $139.00M derived: sum of 3 quarters · filed 2021-03-01 | $167.46M 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $43.35M 10-Q · filed 2019-11-07 | $76.74M derived: sum of 2 quarters · filed 2019-11-07 | $105.20M 10-Q · filed 2019-11-07 | $129.97M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-06-30 | $33.39M 10-Q · filed 2019-08-08 | $61.85M 10-Q · filed 2019-08-08 | $86.62M derived: sum of 3 quarters · filed 2020-02-27 | $107.22M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-03-31 | $28.46M 10-Q · filed 2019-05-09 | $53.23M derived: sum of 2 quarters · filed 2020-02-27 | $73.83M derived: sum of 3 quarters · filed 2020-02-27 | $92.13M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $24.77M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $45.37M derived: sum of 2 quarters · filed 2020-02-27 | $63.66M derived: sum of 3 quarters · filed 2020-02-27 | $81.21M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $20.60M 10-Q · filed 2018-11-06 | $38.89M derived: sum of 2 quarters · filed 2018-11-06 | $56.44M 10-Q · filed 2018-11-06 | $69.91M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-06-30 | $18.30M 10-Q · filed 2018-08-01 | $35.84M 10-Q · filed 2018-08-01 | $49.31M derived: sum of 3 quarters · filed 2019-02-26 | $68.11M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-03-31 | $17.54M 10-Q · filed 2018-05-08 | $31.02M derived: sum of 2 quarters · filed 2019-02-26 | $49.82M derived: sum of 3 quarters · filed 2019-02-26 | $62.81M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2016-12-31 | $13.47M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $32.28M derived: sum of 2 quarters · filed 2019-02-26 | $45.27M derived: sum of 3 quarters · filed 2019-02-26 | $56.51M 10-K · filed 2019-02-26 | ||
| 2016-09-30 | $18.80M 10-Q · filed 2017-11-09 | $31.79M derived: sum of 2 quarters · filed 2017-11-09 | $43.04M 10-Q · filed 2017-11-09 | $59.27M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-06-30 | $12.99M 10-Q · filed 2017-08-07 | $24.24M 10-Q · filed 2017-08-07 | $40.47M derived: sum of 3 quarters · filed 2018-02-27 | $48.58M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | $11.25M 10-Q · filed 2017-05-04 | $27.48M derived: sum of 2 quarters · filed 2018-02-27 | $35.59M derived: sum of 3 quarters · filed 2018-02-27 | $47.10M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $16.23M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $24.34M derived: sum of 2 quarters · filed 2018-02-27 | $35.85M derived: sum of 3 quarters · filed 2018-02-27 | $41.62M 10-K · filed 2018-02-27 | $2.00M 10-K · filed 2016-03-04 | |
| 2015-09-30 | $8.11M 10-Q · filed 2016-11-04 | $19.62M derived: sum of 2 quarters · filed 2016-11-04 | $25.39M 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | $11.51M 10-Q · filed 2016-08-08 | $17.27M 10-Q · filed 2016-08-08 | ||||
| 2015-03-31 | $5.77M 10-Q · filed 2016-05-06 | |||||
| 2014-12-31 | $15.45M 10-K · filed 2017-03-09 | |||||
| 2014-09-30 | $2.00M 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |